SEC Form 4 · accession 0001181431-15-003490
Sagent Pharmaceuticals, Inc. · SGNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lorin Drake
Officer — Executive VP, Sales
Period of report
Feb 25, 2015
Accepted (ET)
Feb 27, 2015 · 3:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2015 | A | 3,683 | $0.00 | A | 27,902 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option to BuyF1 | $27.15 | Feb 25, 2015 | A | 6,840 | A | — | Feb 25, 2025 | Common Stock | 6,840 | 6,840 | D |
Explanation of responses
- F1The option vests in four equal annual installments beginning on February 25, 2016.